PMID- 36327674
OWN - NLM
STAT- MEDLINE
DCOM- 20221128
LR  - 20230818
IS  - 1879-0593 (Electronic)
IS  - 1368-8375 (Linking)
VI  - 135
DP  - 2022 Dec
TI  - The efficacy and safety of VEGF/VEGFR inhibitors in patients with recurrent or 
      metastatic nasopharyngeal carcinoma: A meta-analysis.
PG  - 106231
LID - S1368-8375(22)00520-6 [pii]
LID - 10.1016/j.oraloncology.2022.106231 [doi]
AB  - OBJECTIVES: Molecular targeted therapies against vascular endothelial growth 
      factor (VEGF) receptor (VEGFR) have been explored in the treatment of recurrent 
      or metastatic nasopharyngeal carcinoma (rmNPC). We conducted a meta-analysis to 
      evaluate the efficacy and safety of VEGF/VEGFR inhibitors for treating rmNPC. 
      MATERIALS AND METHODS: Electronic databases were searched for eligible 
      literature. Data on the objective response rate (ORR), disease control rate 
      (DCR), median progression-free survival (mPFS), median overall survival (mOS), 
      PFS rate, OS rate, and drug-related adverse events (AEs) were extracted. RESULTS: 
      A total of 10 studies (published in 9 articles) that involved 357 patients were 
      included. The pooled ORR was 37 % (95 % confidence interval [CI]: 17-60 %), the 
      DCR was 70 % (95 % CI: 51-85 %), the mPFS was 5.69 months (95 % CI: 4.52-6.86), 
      the mOS was 12.61 months (95 % CI: 10.23-14.99), the 1-year PFS rate was 34 % 
      (95 % CI: 25-44 %), and the 1-year OS rate was 62 % (95 % CI: 38-83 %). The 
      pooled incidence of grade 3/4 drug-related AEs was 27 %, while that of grade 5 
      AEs was 0.22 %. Further subgroup analysis showed that the pooled ORR and DCR for 
      first-line VEGF inhibitors were 80 % (95 % CI: 74-86 %) and 94 % (CI: 82-100 %), 
      respectively. CONCLUSION: Our meta-analysis is the first report to demonstrate 
      the efficacy and safety of VEGF/VEGFR inhibitors in patients with rmNPC. 
      Targeting VEGF/VEGFR therapy added to first-line chemotherapy achieved an 
      excellent ORR and DCR, while the improvement in response rates did not translate 
      to a prominent OS benefit.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - Xue, Song
AU  - Xue S
AD  - Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 
      250355, China.
FAU - Song, Ge
AU  - Song G
AD  - Department of Oncology, Shandong Provincial Maternal and Child Health Care 
      Hospital, Jinan 250014, China.
FAU - Zhu, Yingming
AU  - Zhu Y
AD  - Department of Radiation Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing 100021, China.
FAU - Zhang, Nianping
AU  - Zhang N
AD  - Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 
      250355, China.
FAU - Tan, Ying
AU  - Tan Y
AD  - Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 
      250355, China. Electronic address: datanying@126.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221031
PL  - England
TA  - Oral Oncol
JT  - Oral oncology
JID - 9709118
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
CIN - Oral Oncol. 2023 Oct;145:106497. PMID: 37453165
MH  - Humans
MH  - *Vascular Endothelial Growth Factor A
MH  - Nasopharyngeal Carcinoma/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Molecular Targeted Therapy
MH  - *Nasopharyngeal Neoplasms/drug therapy
OTO - NOTNLM
OT  - Adverse events
OT  - Efficacy
OT  - Meta-analysis
OT  - Metastatic
OT  - Nasopharyngeal carcinoma
OT  - Recurrent
OT  - VEGF
OT  - VEGFR
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/11/04 06:00
MHDA- 2022/11/29 06:00
CRDT- 2022/11/03 19:22
PHST- 2022/08/29 00:00 [received]
PHST- 2022/10/20 00:00 [revised]
PHST- 2022/10/23 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/11/29 06:00 [medline]
PHST- 2022/11/03 19:22 [entrez]
AID - S1368-8375(22)00520-6 [pii]
AID - 10.1016/j.oraloncology.2022.106231 [doi]
PST - ppublish
SO  - Oral Oncol. 2022 Dec;135:106231. doi: 10.1016/j.oraloncology.2022.106231. Epub 
      2022 Oct 31.